A Phase I, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously in Patients with Advanced Solid Tumors

Trial Profile

A Phase I, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously in Patients with Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Thioureidobutyronitrile (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Cellceutix
  • Most Recent Events

    • 03 Aug 2016 Results published in the Cellceutix Media Release.
    • 06 Jun 2016 According to a Cellceutix media release, database from this trial will be "soft locked" and will be added to the already prepared documentation for submission to the U.S. FDA in support of the planned Phase 1b/2 trial of Kevetrin in ovarian cancer patients with resistance to platinum-based therapies.
    • 06 Jun 2016 Results published in a Cellceutix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top